Blueprint Medicines Corp Stock Today
| BPMC Stock | USD 93.87 0.28 0.30% |
Performance1 of 100
| Odds Of DistressLess than 42
|
Blueprint Medicines is trading at 93.87 as of the 25th of November 2024, a 0.3% down since the beginning of the trading day. The stock's open price was 94.15. Blueprint Medicines has about a 42 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Blueprint Medicines Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of February 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of April 2015 | Category Healthcare | Classification Health Care |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. The company has 63.53 M outstanding shares of which 4.13 M shares are currently shorted by private and institutional investors with about 6.53 trading days to cover. More on Blueprint Medicines Corp
Moving against Blueprint Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Blueprint Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Kathryn MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBlueprint Medicines can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Blueprint Medicines' financial leverage. It provides some insight into what part of Blueprint Medicines' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Blueprint Medicines Corp (BPMC) is traded on NASDAQ Exchange in USA. It is located in 45 Sidney Street, Cambridge, MA, United States, 02139 and employs 638 people. Blueprint Medicines is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.98 B. Blueprint Medicines Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.53 M outstanding shares of which 4.13 M shares are currently shorted by private and institutional investors with about 6.53 trading days to cover.
Blueprint Medicines Corp currently holds about 853.11 M in cash with (436.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28.
Check Blueprint Medicines Probability Of Bankruptcy
Ownership AllocationThe majority of Blueprint Medicines Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Blueprint Medicines Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Blueprint Medicines. Please pay attention to any change in the institutional holdings of Blueprint Medicines Corp as this could imply that something significant has changed or is about to change at the company.
Check Blueprint Ownership Details
Blueprint Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Lord, Abbett & Co Llc | 2024-09-30 | 1.2 M | |
| Alliancebernstein L.p. | 2024-06-30 | 1.1 M | |
| Pictet Asset Manangement Sa | 2024-06-30 | 1.1 M | |
| Amvescap Plc. | 2024-06-30 | 932.4 K | |
| Woodline Partners Lp | 2024-06-30 | 880.1 K | |
| Polar Capital Holdings Plc | 2024-06-30 | 875 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 842.5 K | |
| American Century Companies Inc | 2024-09-30 | 815.1 K | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 748.7 K | |
| Vanguard Group Inc | 2024-09-30 | 6.7 M | |
| Blackrock Inc | 2024-06-30 | 6.6 M |
Blueprint Medicines Historical Income Statement
Blueprint Stock Against Markets
Blueprint Medicines Corporate Management
| Dr MBA | Chief Officer | Profile | |
| Ariel Hurley | Principal Accounting Officer | Profile | |
| Tracey Esq | Chief VP | Profile | |
| Christina Rossi | Chief Commercial Officer | Profile | |
| Michael CPA | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.